Solid Tumor Oncology

Anatomic Pathology

Morphology

Surgical Pathology Consultation [SPC]

Immunohistochemistry & Special Stains

Refer to A-Z listing for IHC Markers

Cytogenetics

Chromosome Analysis Solid Tumor [CYTO ST]

Molecular Oncology

Next Generation Sequencing (NGS)

BRAF Mutation Analysis [M BRAF]
Colorectal Cancer NGS Panel [M COLON NGS]
(BRAF, KRAS, NRAS)
EGFR Mutation Analysis [M EGFR]
GIST NGS Panel (KIT, PDGFRA, BRAF) [M GIST]
IDH1/IDH2 Mutation Analysis [M IDH1/2]
KRAS Mutation Analysis [M KRAS]
Lung Cancer NGS Panel [M LUNG NGS]
(BRAF, EGFR, KRAS, NRAS)
Melanoma Cancer NGS Panel [M MELAN NGS]
(BRAF, KIT, NRAS)
Solid Tumor 8 Gene NGS Panel [M 8GENE NGS]
(BRAF, EGFR, IDH1, IDH2, KIT, KRAS, NRAS, PDGFRA)

Fluorescence in situ Hybridization

ALK 2p23 rearrangement [FP ALK]
BCL6 3q27 rearrangement [FP BCL6]
Burkitt / "Double Hit" Large B-cell Lymphoma Panel [FP BURKITT]
[C-MYC, BCL2, BCL6]
C MYC 8q24 rearrangement [FP CMYC]
HER2/neu Breast Cancer [FP HER2]
HER2/neu Gastric Cancer [FP HER2 GA]
HER2/neu ALT (D17S122) [FP ALT HER2]
IGH/BCL1 (CCND1) t(11;14) [FP BCL1]
IGH/BCL2 t(14;18) [FP BCL2]
IGH 14q32 rearrangement [FP IGH]
IGH/MALT1 t(14;18) [FP IGH MALT]
IGH/MYC t(8;14) [FP IGH MYC]
MALT1 18q21 rearrangement [FP MALT]
Oligodendroglioma, 1p-;19q- [FP GLI]
Oligodendroglioma, 7p amp [FP EGFR]
Oligodendroglioma, 1p-;19q-, 7p amp [FP GLIO MAP]
ROS1 6q22.1 rearrangement [FP ROS1]

Hematology Oncology

Anatomic Pathology

Morphology

Bone Marrow Pathology Evaluation [BMPE]
Surgical Pathology Consultation [SPC]

Immunohistochemistry & Special Stains

Refer to A-Z listing for IHC Markers

Cytogenetics

Chromosome Analysis Bone Marrow [CYTO BM]
Chromosome Analysis Lymphoma (Lymph Node) [CYTO LN]
Chromosome Analysis Leukemic Peripheral Blood [CYTO LPB]

Flow Cytometry

Flow Cytometry Leukemia / Myeloma / Lymphoma [FLOW]
Flow Cytometry Technical Only [FLOW TC]
Flow Cytometry and Morphology [FLOW M]
Bronchoalveolar Lavage [FLOW BAL]
(CD3, CD4, CD8, CD16, CD45, CD4:CD8 ratio)
Leukocyte Adhesion Deficiency (CD11a, CD11b, CD11c, CD18) [FLOW LAD]
Paroxymal Nocturnal Hemoglobinuria - High Sensitivity
(FLAER, CD14, CD24, CD59) [FLOW PNH]
ZAP-70 [FLOW ZAP 70]

Molecular Oncology

Next Generation Sequencing (NGS)

Calreticulin type 1 / type 2 Mutation Analysis [M CALR]
IgVH Somatic Hypermutation Analysis [M IgVH]
JAK2 Exon 12 Mutation Analysis [M JAK2 EX12]
MPL Exon 10 Mutation Analysis [M MPL]
MYD88 p.L265P Mutation Analysis [M MYD88]
Myeloproliferative Neoplasms Core Mutation Panel
(JAK2 V617F, JAK2 EXON 12, CALR, MPL) [M MPN Core]
Myeloproliferative Neoplasms Extended Mutation Panel
(JAK2 V617F, JAK2 EXON 12, CALR, MPL, ASXL1, CBL, CSF3R, EZH2, IDH1, IDH2, KRAS, NRAS, RUNX1, SETBP1, SF3B1, SRSF2, TET2, TP53) [M MPN Extended]

Polymerase Chain Reaction (PCR)

ABL Kinase Gene Mutation Analysis; Gleevec® Resistance [M ABL G]
AML Mutation Analysis (FLT3 and NPM1) [M AML]
B-cell Immunoglobulin Heavy Chain Gene Rearrangement [M BCELL]
B-cell Immunoglobulin Kappa Light Chain Rearrangement [M IGK]
BCL2 t(14;18) Gene Rearrangement [M BCL2]
BCR/ABL qRT PCR, Major p210 & Minor p190 Mutations [M BCR ABL]
CEBPA Mutation Analysis [M CEBPA]
FLT3 Mutation Analysis [M FLT3]
JAK2 V617F Mutation Analysis [M JAK2]
KIT Mutations in AML [M KIT AML]
KIT D816V Mutation [M KIT P]
NPM1 Mutation Analysis [M NPM1]
PML RARA Short and Long form by qRT PCR [M PML RARA]
T-Cell Receptor Gamma Gene Rearrangement [M TCR]

Fluorescence in situ Hybridization (FISH)

Hematology Panels

Acute Lymphoblastic Leukemia Adult Panel [F AALL]
[t(9;22), t(12;21), MLL(KMTA)]

Burkitt / "Double Hit" Large B-cell Lymphoma Panel [F BURKITT]
[C-MYC, BCL2, BCL6]

Chronic Lymphocytic Leukemia (CLL) Panel [F CLL]
[MYB (6q23), ATM (11q22.3), +12, DLEU1 (13q14.3), TP53 (17p13)]

Myelodysplasia Panel [F MDS] [-5/5q-, -7/7q-, +8, 20q-]

Myeloproliferative Neoplasm Panel [F MPD]
[+8, t(9;22), 13q-, 20q-]

Plasma Cell Neoplasm Panel [F MM]
[1p-, 1q+, +5, +9, t(11;14), 13q-, +15, 17p-]
reflex t(4;14) / t(14;16)

Hematology Probes

AML1(RUNX1)/ETO(RUNXT1) t(8;21) [F AML ETO]
API2/MALT1 t(11;18) [F API MALT]
ATM/CEP11 deletion 11q22.3 [F ATM]
BCL6 3q27 rearrangement [F BCL6]
BCR/ABL1 t(9;22) [F BCR ABL]
CBFB t(16;16), inv(16) [F CBFB]
CEP 7 -7/7q31 [F CEP7]
C MYC 8q24 rearrangement [F CMYC]
Deletion 7q22 [D7S796, D7S658]/7q31.2 [D7S486] [F 7q]
Deletion 13q14.3 [F D1314]
Deletion 20q12 [F D20]
EGR1 5q deletion, monosomy 5 [F EGR1]
FIPIL1/PDGFRA 4q12 gene rearrangement [F 4q12]
IGH/BCL1 (CCND1) t(11;14) [F BCL1]
IGH/BCL2 t(14;18) [F BCL2]
IGH/FGFR3 t(4;14) [F FGFR3]
IGH 14q32 rearrangement [F IGH]
IGH/MAF t(14;16) [F IGH MAF]
IGH/MALT1 t(14;18) [F IGH MALT]
IGH/MYC t(8;14) [F IGH MYC]
MALT1 18q21 rearrangement [F MALT]
MLL(KMT2A) 11q23 Gene Rearrangement [F MLL]
MYB 6q deletion [F MYB]
PDGFRB Gene Rearrangement [F PDGFRB]
PML/RARA t(15,17) [F PML RARA]
TP53 17p13 deletion [F P53]
Trisomy 5, 9, 15 [F T5T9T15]
Trisomy 8 [F T8]
TEL(ETV6)/AML1(RUNX1) t(12;21) [F TEL AML1]

Women's Health

Medical Genetics

Cystic Fibrosis Luminex x-TAG 39 Variant Assay [M CF 39]
Cystic Fibrosis MiSeqDx 139 Variant-Assay by NGS [M CF NGS 139]
Cystic Fibrosis MiSeqDx Clinical Sequence Assay by NGS
[M CF NGS SEQ]

STD and Infectious Disease

Chlamydia Trachomatis, Qualitative by Aptima COMBO® 2 TMA [CT]
Human Papillomavirus Genotyping [HPV G]
Human Papillomavirus High Risk by Aptima HPV [HPV HR]
Herpes Simplex Virus Type 1 and 2 Qualitative by PCR [HSV]
Neisseria Gonorrhoeae Qualitative by Aptima COMBO® 2 TMA [NG]
Trichomonas Vaginalis by Aptima [TV]

Other

Fluorescence in situ Hybridization (FISH)

Bladder Cancer +3,+7,+17,9p21- [F URO]
Molar Pregnancy +13,+18,+21, X, Y [FP ANEU]

Cytogenetics

Chromosome Analysis Peripheral Blood (Constitutional) [CYTO PB]
Chromosome Analysis Products of Conception [CYTO POC]

(Refer to web site for tests performed at affiliate lab)

Rev 03MAY2017